S&P 500   4,366.52 (+0.92%)
DOW   34,262.38 (+0.30%)
QQQ   346.29 (+1.52%)
AAPL   167.74 (+5.35%)
MSFT   303.94 (+1.37%)
FB   298.17 (+1.20%)
GOOGL   2,630.90 (+1.97%)
AMZN   2,815.86 (+0.83%)
TSLA   843.91 (+1.79%)
NVDA   222.81 (+1.54%)
BABA   112.64 (+0.76%)
NIO   20.81 (-1.42%)
AMD   103.53 (+0.91%)
CGC   7.17 (+4.67%)
MU   77.33 (-1.77%)
GE   90.15 (+0.28%)
T   24.58 (+1.91%)
F   19.37 (-0.92%)
DIS   135.72 (+0.22%)
AMC   14.34 (-1.24%)
PFE   54.32 (+1.78%)
ACB   3.88 (+2.37%)
BA   187.88 (-0.99%)
S&P 500   4,366.52 (+0.92%)
DOW   34,262.38 (+0.30%)
QQQ   346.29 (+1.52%)
AAPL   167.74 (+5.35%)
MSFT   303.94 (+1.37%)
FB   298.17 (+1.20%)
GOOGL   2,630.90 (+1.97%)
AMZN   2,815.86 (+0.83%)
TSLA   843.91 (+1.79%)
NVDA   222.81 (+1.54%)
BABA   112.64 (+0.76%)
NIO   20.81 (-1.42%)
AMD   103.53 (+0.91%)
CGC   7.17 (+4.67%)
MU   77.33 (-1.77%)
GE   90.15 (+0.28%)
T   24.58 (+1.91%)
F   19.37 (-0.92%)
DIS   135.72 (+0.22%)
AMC   14.34 (-1.24%)
PFE   54.32 (+1.78%)
ACB   3.88 (+2.37%)
BA   187.88 (-0.99%)
S&P 500   4,366.52 (+0.92%)
DOW   34,262.38 (+0.30%)
QQQ   346.29 (+1.52%)
AAPL   167.74 (+5.35%)
MSFT   303.94 (+1.37%)
FB   298.17 (+1.20%)
GOOGL   2,630.90 (+1.97%)
AMZN   2,815.86 (+0.83%)
TSLA   843.91 (+1.79%)
NVDA   222.81 (+1.54%)
BABA   112.64 (+0.76%)
NIO   20.81 (-1.42%)
AMD   103.53 (+0.91%)
CGC   7.17 (+4.67%)
MU   77.33 (-1.77%)
GE   90.15 (+0.28%)
T   24.58 (+1.91%)
F   19.37 (-0.92%)
DIS   135.72 (+0.22%)
AMC   14.34 (-1.24%)
PFE   54.32 (+1.78%)
ACB   3.88 (+2.37%)
BA   187.88 (-0.99%)
S&P 500   4,366.52 (+0.92%)
DOW   34,262.38 (+0.30%)
QQQ   346.29 (+1.52%)
AAPL   167.74 (+5.35%)
MSFT   303.94 (+1.37%)
FB   298.17 (+1.20%)
GOOGL   2,630.90 (+1.97%)
AMZN   2,815.86 (+0.83%)
TSLA   843.91 (+1.79%)
NVDA   222.81 (+1.54%)
BABA   112.64 (+0.76%)
NIO   20.81 (-1.42%)
AMD   103.53 (+0.91%)
CGC   7.17 (+4.67%)
MU   77.33 (-1.77%)
GE   90.15 (+0.28%)
T   24.58 (+1.91%)
F   19.37 (-0.92%)
DIS   135.72 (+0.22%)
AMC   14.34 (-1.24%)
PFE   54.32 (+1.78%)
ACB   3.88 (+2.37%)
BA   187.88 (-0.99%)
NASDAQ:VINC

Vincerx Pharma News Headlines

$6.87
+0.10 (+1.48%)
(As of 01/28/2022 11:37 AM ET)
Add
Compare
Today's Range
$6.61
$6.90
50-Day Range
$6.77
$12.56
52-Week Range
$6.23
$26.75
Volume
1,211 shs
Average Volume
149,766 shs
Market Capitalization
$144.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Get Vincerx Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for VINC and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

Vincerx Pharma Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

VINC
News Sentiment

0.00

0.27

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

VINC Articles
This Week

0

0

VINC Articles
Average Week



Vincerx Pharma (NASDAQ:VINC) News Headlines Today

SourceHeadline
MarketBeat logoVincerx Pharma (NASDAQ:VINC) Receives New Coverage from Analysts at HC Wainwright
americanbankingnews.com - January 14 at 8:52 AM
nasdaq.com logoBullish Vincerx Pharma, Inc. (NASDAQ:VINC) insiders filled their treasuries with US$741k worth of stock over last year
nasdaq.com - December 28 at 2:28 PM
finance.yahoo.com logoVincerx Pharma, Inc. (NASDAQ:VINC) insiders placed bullish bets worth US$741k in the last 12 months
finance.yahoo.com - December 28 at 2:28 PM
benzinga.com logoCantor Fitzgerald Initiates Coverage On Vincerx Pharma with Overweight Rating, Announces Price Target of $25
benzinga.com - December 24 at 8:23 AM
finance.yahoo.com logoVincerx Pharma Announces First Patient Dosed in Phase 1 Dose-Escalation Study of VIP152 in Relapsed or Refractory Chronic Lymphocytic Leukemia or Richter Syndrome
finance.yahoo.com - December 17 at 12:45 PM
finance.yahoo.com logoVincerx Pharma Announces Presentations at the American Society of Hematology Annual Meeting
finance.yahoo.com - November 4 at 10:06 AM
finance.yahoo.com logoVincerx Pharma Announces $50 Million Private Placement
finance.yahoo.com - September 16 at 8:25 AM
finance.yahoo.com logoVincerx Pharma to Participate in the 2021 Wells Fargo Virtual Healthcare Conference
finance.yahoo.com - September 7 at 8:13 AM
barrons.com logoVincerx Pharma Inc.
barrons.com - August 21 at 9:24 AM
finance.yahoo.com logoVincerx Pharma Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
finance.yahoo.com - August 12 at 8:21 PM
finance.yahoo.com logoIs Vincerx Pharma, Inc. (VINC) A Good Stock To Buy?
finance.yahoo.com - July 30 at 12:48 PM
nasdaq.com logoThursday 7/1 Insider Buying Report: VINC, FULC
nasdaq.com - July 1 at 3:33 PM
finance.yahoo.com logoInsider Buying: The Vincerx Pharma, Inc. (NASDAQ:VINC) Independent Director Just Bought US$126k Worth Of Shares
finance.yahoo.com - July 1 at 10:33 AM
msn.com logoBRIEF-Vincerx Pharma Presents Clinical Data on VIP512, Its PTEFb/CDK9 Inhibitor, In Patients With Double-Hit Lymphoma At ASCO 2021
msn.com - June 4 at 12:42 PM
finance.yahoo.com logoVincerx Pharma Announces First Patient Dosed in Phase 1b Study of VIP152 in MYC-Driven Relapsed or Refractory Aggressive Lymphomas and Advanced Solid Tumors
finance.yahoo.com - June 3 at 8:04 PM
Get Vincerx Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for VINC and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 1/28/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.